AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
The pharmaceutical company hopes that another big-time acquisition will pay off.
The pharmaceutical company hopes that another big-time acquisition will pay off.
BELLINGS Intelligence Score: 18
Why it matters
AbbVie's $8 billion debt raise for an acquisition is a sizable but routine corporate financing event typical in large-cap M&A activity, unlikely to alter credit market structure or underwriting standards materially.